German Social Democrats boost support for biotechnology
This article was originally published in Clinica
Executive Summary
Developments in biomedical research are improving our understanding of human diseases and providing new opportunities in diagnosis and therapy, says the German Social Democratic Party (SPD). Delegates at the SPD annual congress in Nuremberg last week announced that the party would intensify its support for companies that developed innovative medical products and procedures in the biomedical sector. "We should not close any doors," said research minister Edelgard Buhlmann.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.